BACKGROUND: In 2014, approximately 40,000 persons in the United States received a diagnosis of human immunodeficiency virus (HIV) infection. Preexposure prophylaxis (PrEP) with daily oral antiretroviral medication is a new, highly effective intervention that could reduce the number of new HIV infections. METHODS: CDC analyzed nationally representative data to estimate the percentages and numbers of persons in the United States, by transmission risk group, with indications for PrEP consistent with the 2014 U.S. Public Health Service's PrEP clinical practice guideline. RESULTS: Approximately 24.7% of sexually active adult men who have sex with men (MSM) (492,000 [95% confidence interval {CI} = 212,000-772,000]), 18.5% of persons who inject drugs (115,000 [CI = 45,000-185,000]), and 0.4% of heterosexually active adults (624,000 [CI = 404,000-846,000]), had substantial risks for acquiring HIV consistent with PrEP indications. CONCLUSIONS: Based on current guidelines, many MSM, persons who inject drugs, and heterosexually active adults have indications for PrEP. A higher percentage of MSM and persons who inject drugs have indications for PrEP than heterosexually active adults, consistent with distribution of new HIV diagnoses across these populations. IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Clinical organizations, health departments, and community-based organizations should raise awareness of PrEP among persons with substantial risk for acquiring HIV infection and their health care providers. These data can be used to inform scale-up and evaluation of PrEP coverage. Increasing delivery of PrEP and other highly effective HIV prevention services could lower the number of new HIV infections occurring in the United States each year.
BACKGROUND: In 2014, approximately 40,000 persons in the United States received a diagnosis of human immunodeficiency virus (HIV) infection. Preexposure prophylaxis (PrEP) with daily oral antiretroviral medication is a new, highly effective intervention that could reduce the number of new HIV infections. METHODS: CDC analyzed nationally representative data to estimate the percentages and numbers of persons in the United States, by transmission risk group, with indications for PrEP consistent with the 2014 U.S. Public Health Service's PrEP clinical practice guideline. RESULTS: Approximately 24.7% of sexually active adult men who have sex with men (MSM) (492,000 [95% confidence interval {CI} = 212,000-772,000]), 18.5% of persons who inject drugs (115,000 [CI = 45,000-185,000]), and 0.4% of heterosexually active adults (624,000 [CI = 404,000-846,000]), had substantial risks for acquiring HIV consistent with PrEP indications. CONCLUSIONS: Based on current guidelines, many MSM, persons who inject drugs, and heterosexually active adults have indications for PrEP. A higher percentage of MSM and persons who inject drugs have indications for PrEP than heterosexually active adults, consistent with distribution of new HIV diagnoses across these populations. IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Clinical organizations, health departments, and community-based organizations should raise awareness of PrEP among persons with substantial risk for acquiring HIV infection and their health care providers. These data can be used to inform scale-up and evaluation of PrEP coverage. Increasing delivery of PrEP and other highly effective HIV prevention services could lower the number of new HIV infections occurring in the United States each year.
Authors: Alisse Hannaford; Madeleine Lipshie-Williams; Joanna L Starrels; Julia H Arnsten; Jessica Rizzuto; Phillip Cohen; Damon Jacobs; Viraj V Patel Journal: AIDS Behav Date: 2018-04
Authors: Chen Zhang; James McMahon; Kevin Fiscella; Sarahmona Przybyla; Amy Braksmajer; Natalie LeBlanc; Yu Liu Journal: AIDS Patient Care STDS Date: 2019-12 Impact factor: 5.078
Authors: Meredith L Brantley; Peter F Rebeiro; April C Pettit; Allison Sanders; Lyle Cooper; Shanell McGoy; Melissa Morrison Journal: AIDS Behav Date: 2019-10
Authors: Jill Blumenthal; Raphael Landovitz; Sonia Jain; Feng He; Ryan Kofron; Eric Ellorin; Gifty M Ntim; Jamila K Stockman; Katya Corado; K Rivet Amico; David J Moore; Sheldon Morris Journal: AIDS Patient Care STDS Date: 2021-12 Impact factor: 5.944
Authors: Oliver Bacon; Rafael Gonzalez; Erin Andrew; Michael B Potter; James R Iñiguez; Stephanie E Cohen; Albert Y Liu; Jonathan D Fuchs Journal: J Acquir Immune Defic Syndr Date: 2017-02-01 Impact factor: 3.731
Authors: Daniel E Mauck; Kristopher P Fennie; Gladys E Ibañez; Eric A Fenkl; Diana M Sheehan; Lorene M Maddox; Emma C Spencer; Mary Jo Trepka Journal: Ann Epidemiol Date: 2020-02-14 Impact factor: 3.797
Authors: Ian W Holloway; Ryan Dougherty; Jennifer Gildner; Sean C Beougher; Craig Pulsipher; Jorge A Montoya; Aaron Plant; Arleen Leibowitz Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.771
Authors: Erika Aaron; Cori Blum; Dominika Seidman; Mary Jo Hoyt; Joanne Simone; Meg Sullivan; Dawn K Smith Journal: AIDS Patient Care STDS Date: 2018-01 Impact factor: 5.078
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Judy Shigenaga; Kimberly A Spaulding; David V Glidden; Megha L Mehrotra; Patricia Defechereux; Monica Gandhi; Robert M Grant; Michael G Shlipak; Vasantha Jotwani Journal: AIDS Date: 2020-04-01 Impact factor: 4.632